List of Excipients in Branded Drug OJEMDA

OJEMDA Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

OJEMDA (tovorafenib) is a targeted RAF kinase inhibitor developed by Day One Biopharmaceuticals and approved by the FDA on April 23, 2024, for patients at least 6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or BRAF V600 mutation. Its commercial value depends on more than the active ingredient. Pediatric dosing, swallowing limitations, chronic administration, caregiver handling, storage, and global distribution make the excipient system and dosage-form architecture material to market access and lifecycle protection.[1]

The strongest commercial opportunity is the pediatric oral suspension. It expands access to infants, young children, and patients unable to swallow tablets while supporting weight- or body-surface-area-based dosing. Excipient optimization can improve adherence, reduce preparation errors, extend in-use stability, and create formulation, device, and manufacturing barriers around the branded product.

What is OJEMDA and which dosage forms are commercially available?

OJEMDA contains tovorafenib, a type II pan-RAF kinase inhibitor. The approved regimen is 380 mg/m² orally once weekly, up to a maximum of 600 mg per dose. OJEMDA is supplied as tablets and as powder for oral suspension, with the suspension reconstituted by a pharmacy before dispensing.[1]

Product attribute	OJEMDA status
Active ingredient	Tovorafenib
Sponsor	Day One Biopharmaceuticals
FDA approval	April 23, 2024
Indication	Relapsed or refractory pediatric low-grade glioma
Molecular criteria	BRAF fusion, BRAF rearrangement, or BRAF V600 mutation
Minimum age	6 months
Administration	Once weekly
Dose	380 mg/m², maximum 600 mg
Dosage forms	Tablets and powder for oral suspension
Therapeutic category	Pediatric oncology, RAF/MAPK pathway inhibition

The two dosage forms address different use cases. Tablets are operationally simpler for older children and adolescents. The suspension is more important for patients with dysphagia, low body weight, dose-escalation needs, or an inability to reliably swallow solid oral dosage forms.

What excipients are important in the OJEMDA formulation?

The FDA-approved product uses conventional solid-dose and oral-suspension excipient technologies. The commercial question is not whether the excipients are novel individually. It is whether their combination supports dose uniformity, physical stability, palatability, reconstitution, and reliable home administration.[1]

Relevant excipient functions include:

Excipient function	Commercial and technical purpose
Bulking agent	Provides tablet or powder mass and supports dose handling
Binder	Improves granule and tablet integrity
Disintegrant	Promotes tablet breakup and drug release
Wetting agent	Improves dispersion of hydrophobic drug particles
Suspending agent	Limits sedimentation and supports dose uniformity
Lubricant	Improves tablet manufacture and ejection
Glidant	Improves powder flow and fill-weight control
Flavoring system	Reduces bitterness and improves pediatric acceptance
Buffer or pH modifier	Controls chemical stability and taste
Preservative, where required	Controls microbial growth during in-use storage

The label identifies inactive ingredients for the approved dosage forms. A detailed formulation assessment should distinguish the excipients present in the commercial tablet from those present in the reconstituted suspension because the risk profile differs. Tablets are primarily exposed to compression, disintegration, dissolution, and solid-state stability risks. The suspension is exposed to sedimentation, caking, microbial control, viscosity drift, reconstitution variability, dosing-device compatibility, and in-use stability risks.[1]

Which excipient risks matter most in pediatric oncology?

Pediatric oncology products require a narrower risk tolerance than conventional adult tablets. Small dosing errors can materially affect exposure, particularly when the dose is calculated from body surface area and administered at home.

The principal risks are:

1. Taste and mouthfeel. Tovorafenib’s bitterness, the surfactant system, and suspension viscosity can affect acceptance.
2. Dose uniformity. The suspension must remain sufficiently homogeneous during the time between shaking and administration.
3. Reconstitution error. Incorrect water volume or inadequate shaking can create underdosing or overdosing.
4. In-use stability. Families may store and use the product for weeks, creating chemical and microbiological control requirements.
5. Dosing-device accuracy. Oral syringes must deliver the intended volume at pediatric doses.
6. Excipient exposure. The formulation should avoid unnecessary ethanol, propylene glycol, benzyl alcohol, high sodium, and excessive sugar where feasible.
7. Administration compatibility. The product should not require complex food mixing or manipulation that increases variability.

How does the OJEMDA oral suspension create commercial opportunity?

The oral suspension is the main formulation-led growth platform for OJEMDA. It can increase the addressable treated population without changing the active ingredient or approved indication.

Infants and younger children

The FDA label permits use from 6 months of age. Many patients in this group cannot swallow tablets. A ready-to-use or pharmacy-reconstituted suspension reduces the need for tablet crushing, which can create dose loss, inconsistent dispersion, occupational exposure, and off-label manipulation concerns.

Weight-based dosing

A liquid dosage form allows more precise volume adjustment as a child grows. This is important for a weekly dose calculated at 380 mg/m². A 25 mg/mL concentration, if maintained in the commercial presentation, supports practical volume measurement across pediatric body sizes while limiting total administration volume.

Adherence and persistence

Once-weekly dosing is commercially favorable, but adherence can still be affected by taste, preparation steps, and caregiver burden. Improvements in flavor, syringe design, bottle geometry, and shake instructions can protect persistence without changing the pharmacology.

Hospital-to-home transition

A stable suspension supports discharge from hospital or specialty clinic to home treatment. This can reduce dependence on compounding pharmacies and standardize administration across academic centers, community oncology practices, and specialty pharmacies.

International commercialization

Excipients permitted in the United States may face different requirements in the European Union, Japan, or other markets. A global formulation strategy should minimize region-specific excipients, avoid animal-derived materials where possible, and account for local limits on preservatives, solvents, sugars, and elemental impurities.

What formulation patents could protect OJEMDA?

Formulation protection is most valuable where it solves a measurable pediatric administration problem. A patent directed only to a broad list of conventional excipients may face validity and obviousness pressure. Stronger claims would connect composition to technical performance.

Potential claim areas include:

Patent area	Protectable technical subject matter
Oral suspension	Concentration, particle-size distribution, viscosity, sedimentation control, and redispersibility
Taste masking	Coating, ion-pairing, complexation, flavor system, or bitterness threshold
Reconstitution	Powder blend, water volume, reconstitution time, and final suspension properties
Stability	Chemical degradation control and specified shelf-life or in-use period
Device	Bottle, adapter, oral syringe, cap, or dose-delivery system
Manufacturing	Milling, granulation, drying, blending, filling, and scale-up parameters
Solid dosage form	Polymorph, amorphous dispersion, dissolution profile, and tablet robustness
Administration method	Suspension dosing for defined pediatric weight or body-surface-area ranges

The strongest commercial position would combine composition-of-matter protection for tovorafenib with narrower formulation patents and regulatory exclusivity. Formulation patents can be valuable after the core molecule patent expires, but they must be drafted around reproducible physical or clinical advantages.

What is the FDA exclusivity timeline for OJEMDA?

OJEMDA has several potential layers of FDA exclusivity. The exact end dates depend on the FDA’s regulatory records, patent term adjustments, pediatric-extension status, and the scope of any orphan designation.

Exclusivity category	Potential duration or status
New chemical entity exclusivity	Five years from approval, subject to statutory exceptions
Orphan-drug exclusivity	Seven years for the approved rare-disease indication if applicable
Pediatric exclusivity	Six-month extension if FDA-granted after completion of qualifying studies
Patent protection	Depends on issued patents, expiration dates, term adjustment, and terminal disclaimers
Formulation protection	Depends on issued claims and enforceability
Data protection	Linked to the applicable FDA approval and regulatory pathway

The orphan exclusivity period is commercially important because it can restrict approval of the same drug for the same indication, even when no patent infringement is established. It does not block all competing products or all uses of tovorafenib.

When could generic or competitive entry affect OJEMDA?

A conventional generic challenge would likely focus on the tablet or suspension through an abbreviated new drug application and Paragraph IV certification against Orange Book-listed patents. The risk profile depends on which patents are listed and whether they cover the active ingredient, dosage form, method of use, or manufacturing process.

Potential entry scenarios include:

Tablet-only generic entry

A tablet competitor may seek approval for patients able to swallow solid dosage forms. It could avoid some suspension-specific formulation claims but would still face active-ingredient, method-of-use, and tablet-composition patents.

Suspension competition

A suspension entrant would face greater technical and regulatory barriers. It would need to demonstrate dose uniformity, stability, reconstitution performance, microbiological quality, and acceptable dosing-device performance.

Alternative RAF inhibitors

A competing targeted therapy may not need to establish pharmaceutical equivalence to OJEMDA. It could compete through a different active ingredient, a different BRAF or MEK pathway mechanism, or a broader molecular indication. This creates greater commercial risk than a standard generic in a biomarker-defined pediatric market.

Compounded products

Compounding could emerge where the branded suspension is unavailable or unaffordable. Compounded products may have weaker stability, taste, dose-uniformity, and quality documentation. A well-designed commercial suspension can reduce this substitution risk.

Which companies challenge or compete with OJEMDA?

No broad commercial generic market has been established for tovorafenib at the time of FDA approval. Competitive pressure is more likely to come from other pediatric low-grade glioma treatments and MAPK-pathway inhibitors.

Relevant competitive categories include:

Competitor category	Commercial relevance
BRAF inhibitors	May compete in BRAF V600-mutated disease
MEK inhibitors	May compete in BRAF-altered or MAPK-driven tumors
Chemotherapy	Remains relevant in pediatric low-grade glioma treatment sequencing
Clinical trials	Can divert relapsed or refractory patients
Future RAF inhibitors	Could compete for BRAF fusion or rearrangement populations
Compounded formulations	Could substitute for branded liquid dosing in limited settings

The most direct threat is a therapy with an overlapping biomarker population, pediatric labeling, oral administration, and a tolerable long-term safety profile. Competitive differentiation will depend on response durability, central nervous system activity, dosing convenience, age eligibility, and access.

How strong is the OJEMDA excipient and formulation patent estate?

The formulation estate is potentially moderate to strong if it protects the suspension’s measurable performance rather than conventional excipient selection alone.

Factors supporting strength

• Pediatric indication beginning at 6 months.
• Need for body-surface-area-based dosing.
• Two approved dosage forms with distinct administration requirements.
• Potential technical complexity in suspension stability and dose uniformity.
• Limited ability of caregivers to manipulate tablets safely.
• Commercial value of a reliable liquid product in a rare-disease setting.

Factors limiting strength

• Conventional excipients may be vulnerable to obviousness arguments.
• Generic applicants may use different excipients while achieving pharmaceutical equivalence.
• A method-of-use patent may not block off-label use of a competing RAF inhibitor.
• Orphan exclusivity protects the indication, not every formulation.
• Suspension patents must withstand challenges based on routine optimization.

A layered strategy is more defensible than relying on a single excipient patent. The preferred structure includes a core active-ingredient patent, formulation claims, reconstitution and stability claims, device claims, and manufacturing know-how.

What licensing and partnering opportunities exist for OJEMDA?

The most likely partnership opportunities are outside the active ingredient itself.

Regional commercialization

Day One can use regional partners for registration, specialty distribution, and pediatric oncology market access. A partner with established rare-disease infrastructure may reduce launch costs in Europe and Asia.

Formulation technology

Excipient suppliers and drug-delivery companies can contribute taste masking, suspension stabilization, powder-for-reconstitution, or oral-syringe systems. The highest-value deals would link formulation rights to clinical or manufacturing milestones.

Contract manufacturing

Commercial-scale powder filling, bottle assembly, reconstitution packaging, and quality control are potential outsourcing areas. Manufacturing partners with pediatric liquid experience may reduce scale-up and supply risk.

Diagnostic partnerships

Because treatment depends on BRAF fusion, rearrangement, or V600 status, diagnostic partnerships can improve patient identification and reduce treatment delays. This is a commercial infrastructure opportunity rather than an excipient opportunity.

What regulatory and manufacturing barriers affect OJEMDA?

The suspension creates a higher manufacturing burden than a conventional tablet. Critical controls include:

• Particle size and milling endpoint.
• Blend uniformity for low-dose powder components.
• Reconstitution volume and water quality.
• Shake-time instructions.
• Sedimentation and redispersion.
• Microbial limits and preservative performance.
• Bottle and closure extractables and leachables.
• Oral-syringe compatibility.
• In-use chemical and microbiological stability.
• Shipping exposure to heat, cold, and vibration.

A commercial product that reduces these variables can command a stronger institutional preference even without a new clinical indication. Specialty pharmacies and pediatric oncology centers generally value fewer preparation steps, clear dosing instructions, and predictable supply.

What revenue exposure and commercial expansion opportunities exist?

OJEMDA’s revenue opportunity is concentrated in a small but highly specialized population. The product’s value per treated patient can be high because pediatric oncology therapies are typically reimbursed through specialty channels and may be used over extended treatment periods.

Expansion opportunities include:

1. Earlier-line treatment in pediatric low-grade glioma.
2. Additional BRAF-altered central nervous system tumors.
3. Adult or adolescent tumors with RAF fusions or related MAPK alterations.
4. Combination regimens with other pathway inhibitors.
5. Global registrations supported by the liquid dosage form.
6. New concentrations or ready-to-use presentations.
7. Improved packaging for home administration.
8. Companion-diagnostic and testing-network expansion.

The main commercial constraint is the biomarker-defined population. The principal formulation opportunity is to capture the full age range authorized by the label and make weekly treatment practical outside specialized hospitals.

Key Takeaways

• OJEMDA is an FDA-approved tovorafenib product for pediatric low-grade glioma with specified BRAF alterations.
• The oral suspension is the most commercially important dosage form for infants, young children, and patients unable to swallow tablets.
• Excipient strategy should prioritize taste, dose uniformity, reconstitution, in-use stability, and device compatibility.
• Formulation patents are strongest when tied to measurable technical performance rather than broad conventional excipient combinations.
• Generic risk may arise through tablet, suspension, or alternative-excipient approaches, while branded competition may come from other BRAF and MEK pathway therapies.
• A layered IP strategy should combine active-ingredient, formulation, device, manufacturing, and regulatory exclusivity.
• Commercial expansion is most likely through earlier-line use, broader BRAF-altered tumors, international launches, and improved pediatric delivery systems.

FAQs

Can OJEMDA tablets be crushed and administered as a liquid?

The FDA-approved product includes a powder for oral suspension. Tablet manipulation should not be treated as equivalent to the approved suspension because crushing can affect dose recovery, dispersion, caregiver exposure, and administration accuracy.[1]

Why is a powder for oral suspension commercially preferable to a compounded liquid?

A manufactured powder can provide validated concentration, shelf life, reconstitution instructions, microbial controls, and device compatibility. A compounded liquid may have greater variability in stability and dose uniformity.

Can excipient patents delay tovorafenib generic entry?

They can delay or complicate entry if the generic product would infringe valid, enforceable claims. Generic applicants may avoid infringement by using different excipients or manufacturing conditions while meeting FDA equivalence requirements.

What is the highest-value improvement to OJEMDA’s pediatric formulation?

The highest-value improvement is a formulation that combines reliable dose uniformity with better taste and fewer preparation steps. A ready-to-use suspension or an improved reconstitution system could reduce caregiver burden and substitution risk.

Does OJEMDA have biosimilar risk?

No. Tovorafenib is a small-molecule drug, so the relevant competitive pathways are generic-drug applications, alternative small-molecule therapies, and competing targeted treatments rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2024). OJEMDA (tovorafenib) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024, April 23). FDA approves tovorafenib for relapsed or refractory pediatric low-grade glioma. FDA.
3. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
4. Day One Biopharmaceuticals, Inc. (2024). OJEMDA product information and investor materials. Day One Biopharmaceuticals.